HANGZHOU ALLTEST BIOTECH CO., LTD. Financials Hangzhou Alltest Biotech Co., Ltd.
Equities
688606
CNE1000053G6
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.39 CNY | -2.66% |
|
-6.34% | -17.80% |
| Apr. 29 | China, HK stocks rise, led by property shares | RE |
| Apr. 26 | Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 6,631 | 5,519 | 5,362 |
| Enterprise Value (EV) 1 | 3,709 | 1,726 | 2,597 |
| P/E ratio | 8.12 x | 4.75 x | 30.1 x |
| Yield | 3.25% | 9.58% | 2.19% |
| Capitalization / Revenue | 3.54 x | 1.63 x | 7.1 x |
| EV / Revenue | 1.98 x | 0.51 x | 3.44 x |
| EV / EBITDA | 4.38 x | 1.25 x | 21.6 x |
| EV / FCF | 6.97 x | 2.17 x | -4.03 x |
| FCF Yield | 14.4% | 46% | -24.8% |
| Price to Book | 2.03 x | 1.32 x | 1.4 x |
| Nbr of stocks (in thousands) | 79,778 | 78,245 | 78,157 |
| Reference price 2 | 83.11 | 70.54 | 68.60 |
| Announcement Date | 4/27/22 | 4/29/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 183.8 | 241.3 | 1,136 | 1,873 | 3,389 | 754.7 |
| EBITDA 1 | 62.1 | 80.58 | 807.1 | 846.5 | 1,378 | 120.2 |
| EBIT 1 | 59.76 | 77.47 | 803.1 | 837.7 | 1,354 | 99.01 |
| Operating Margin | 32.51% | 32.1% | 70.72% | 44.71% | 39.97% | 13.12% |
| Earnings before Tax (EBT) 1 | 62.76 | 87.95 | 791.7 | 895.5 | 1,381 | 197.4 |
| Net income 1 | 56.72 | 78.42 | 679.2 | 765.7 | 1,184 | 180.6 |
| Net margin | 30.86% | 32.49% | 59.81% | 40.87% | 34.96% | 23.93% |
| EPS 2 | 0.9662 | 1.311 | 11.36 | 10.24 | 14.84 | 2.280 |
| Free Cash Flow 1 | -64.08 | 47.56 | 399 | 532.3 | 793.8 | -644.7 |
| FCF margin | -34.86% | 19.7% | 35.14% | 28.41% | 23.43% | -85.42% |
| FCF Conversion (EBITDA) | - | 59.01% | 49.44% | 62.89% | 57.63% | - |
| FCF Conversion (Net income) | - | 60.64% | 58.75% | 69.52% | 67.02% | - |
| Dividend per Share | - | - | 1.351 | 2.703 | 6.757 | 1.500 |
| Announcement Date | 6/21/19 | 3/4/21 | 4/28/21 | 4/27/22 | 4/29/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 46.9 | 125 | 701 | 2,922 | 3,793 | 2,765 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -64.1 | 47.6 | 399 | 532 | 794 | -645 |
| ROE (net income / shareholders' equity) | 32% | 30.9% | 107% | 36.1% | 31.8% | 4.51% |
| ROA (Net income/ Total Assets) | 16.8% | 16.5% | 67.7% | 20.3% | 19.4% | 1.4% |
| Assets 1 | 338 | 475.4 | 1,004 | 3,773 | 6,092 | 12,856 |
| Book Value Per Share 2 | 3.600 | 4.900 | 16.30 | 41.00 | 53.20 | 49.00 |
| Cash Flow per Share 2 | 0.2000 | 1.060 | 4.780 | 27.30 | 25.30 | 16.90 |
| Capex 1 | 35.1 | 15.1 | 37.1 | 140 | 270 | 533 |
| Capex / Sales | 19.07% | 6.25% | 3.27% | 7.48% | 7.98% | 70.69% |
| Announcement Date | 6/21/19 | 3/4/21 | 4/28/21 | 4/27/22 | 4/29/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -17.80% | 620M | |
| -5.86% | 12.09B | |
| -4.87% | 8.21B | |
| +5.47% | 5.74B | |
| +27.42% | 5.64B | |
| -9.89% | 4.16B | |
| -58.99% | 2.88B | |
| +8.97% | 2.69B | |
| -5.19% | 2.33B | |
| +21.58% | 2.17B |
- Stock Market
- Equities
- 688606 Stock
- Financials Hangzhou Alltest Biotech Co., Ltd.
